Clinical trials recruiting in Shandong, China

Phase breakdown

Conditions recruiting in Shandong, China

Recruiting trials in Shandong, China

• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
  NCT07205822 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Chinese Psoriasis Real World Evidence Research
  NCT04465838 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
  NCT06809764 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
  NCT06993844 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
  NCT04686305 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
  NCT06005493 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Shandong, China?

11 recruiting trials have at least one study site in Shandong, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.